GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Incyte Corporation (INCY) [hlAlert]

Rating:
Overweight
INCY
up 91.05 %

Incyte Corporation (INCY) rated Overweight with price target $125 by Barclays

Posted on: Thursday,  Aug 13, 2015  12:25 PM ET by Barclays

Barclays rated Overweight Incyte Corporation (NASDAQ: INCY) on 08/13/2015. Previously Barclays rated Overweight Incyte Corporation (NASDAQ: INCY) on 01/10/2014., when
the stock price was $59.59. Since then, Incyte Corporation has gained 91.06% as of 01/14/2016's recent price of $113.85.
If you would have followed the previous Barclays's recommendation on INCY, you would have gained 91.05% of your investment in 734 days.

Incyte Corporation (Incyte) is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs. The Company has a pipeline with programs in oncology, inflammation and diabetes. Incyte?s pipeline includes compounds in various stages of development in the areas of oncology, inflammation, diabetes and human immunodeficiency virus (HIV).

Barclays
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/13/2015 12:25 PM Buy
None
108.44 125.00
as of 8/27/2015
1 Week up  11.61 %
1 Month up  4.15 %
3 Months up  6.62 %
1 YTD up  4.98 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/13/2014 12:25 PM Buy
None
66.00 75.00
1/10/2014 1:25 PM Buy
None
59.59 64.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy